Inside the deadly disease confounding medicine, researchers piecing together clues and the breakthrough that meant survival ...
Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial ...
(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 ...
The best ways to get rid of phlegm, from using nasal sprays to taking the right OTC medications. Plus, they explain what ...
Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...
Biologics represent a breakthrough in the management of airway diseases, offering precision treatments that target specific immune pathways. This special issue, Biologics for Airway Diseases: From ...
Experiencing breathing difficulties Learn about dyspnoea shortness of breath including its main causes symptoms and ...
Scott Brooks, from Maltby, was just 17 when he started smoking, saying it was just "the norm" for the 1980s. But after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results